Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 50,000 Shares

Posted by Brian Himes on Jul 9th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 50,000 shares of Liquidia stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $80.94, for a total transaction of $4,047,000.00. Following the completion of the transaction, the director owned 780,073 shares in the company, valued at approximately $63,139,108.62. This trade represents a 6.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $79.47 on Thursday. Liquidia Corporation has a one year low of $12.88 and a one year high of $82.96. The stock has a fifty day moving average of $63.33 and a 200-day moving average of $46.35. The company has a market capitalization of $7.07 billion, a PE ratio of 567.68 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, equities analysts anticipate that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LQDA has been the topic of a number of analyst reports. Oppenheimer set a $75.00 price target on Liquidia in a research note on Friday, June 5th. Needham & Company LLC upped their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. BTIG Research raised their price objective on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Raymond James Financial reissued a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research note on Thursday, June 4th. Finally, Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.88.

Get Our Latest Stock Analysis on Liquidia

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares in the last quarter. Creative Planning raised its position in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after acquiring an additional 11,111 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).